916 results on '"Go R"'
Search Results
302. Gene expression of cytochrome P4501A1 was involved in the alteration of cell function by dioxinvia estrogen receptor in cellular and xenografted ovarian cancer models.
- Author
-
Go, R.-E., Lee, M.-Y., and Choi, K.-C.
- Subjects
- *
GENE expression , *CYTOCHROMES , *CELL physiology , *ESTROGEN receptors , *XENOGRAFTS , *OVARIAN cancer - Published
- 2015
- Full Text
- View/download PDF
303. Expressions of metastasis-related genes appeared to be altered by treatment with fenhexamid and cyprodinil in an ovarian cancer cell model.
- Author
-
Go, R.-E. and Choi, K.-C.
- Subjects
- *
METASTASIS , *GENE expression , *FENHEXAMID , *CYPRODINIL , *OVARIAN cancer treatment , *CANCER cells - Published
- 2015
- Full Text
- View/download PDF
304. Erratum for ‘Room-temperature continuous-wave operation of long wavelength (λ=9.5 µm) MOVPE-grown quantum cascade lasers’.
- Author
-
Pflügl, C., Diehl, L., Tsekoun, A., Go, R., Patel, C.K.N., Wang, X., Fan, J., Tanbun-Ek, T., and Capasso, F.
- Subjects
LASERS - Abstract
A correction to the article "Room-temperature continuous-wave operation of long wavelength (λ=9.5 μm) MOVPE-grown quantum cascade lasers" that was published in the previous issue is presented.
- Published
- 2007
- Full Text
- View/download PDF
305. Interleukin 2 and HIV RNA Levels.
- Author
-
Go R and Steigbigel R
- Published
- 2007
306. Comparison of measures of marker informativeness for ancestry and admixture mapping
- Author
-
Ding Lili, Wiener Howard, Abebe Tilahun, Altaye Mekbib, Go Rodney CP, Kercsmar Carolyn, Grabowski Greg, Martin Lisa J, Khurana Hershey Gurjit K, Chakorborty Ranajit, and Baye Tesfaye M
- Subjects
Biotechnology ,TP248.13-248.65 ,Genetics ,QH426-470 - Abstract
Abstract Background Admixture mapping is a powerful gene mapping approach for an admixed population formed from ancestral populations with different allele frequencies. The power of this method relies on the ability of ancestry informative markers (AIMs) to infer ancestry along the chromosomes of admixed individuals. In this study, more than one million SNPs from HapMap databases and simulated data have been interrogated in admixed populations using various measures of ancestry informativeness: Fisher Information Content (FIC), Shannon Information Content (SIC), F statistics (FST), Informativeness for Assignment Measure (In), and the Absolute Allele Frequency Differences (delta, δ). The objectives are to compare these measures of informativeness to select SNP markers for ancestry inference, and to determine the accuracy of AIM panels selected by each measure in estimating the contributions of the ancestors to the admixed population. Results FST and In had the highest Spearman correlation and the best agreement as measured by Kappa statistics based on deciles. Although the different measures of marker informativeness performed comparably well, analyses based on the top 1 to 10% ranked informative markers of simulated data showed that In was better in estimating ancestry for an admixed population. Conclusions Although millions of SNPs have been identified, only a small subset needs to be genotyped in order to accurately predict ancestry with a minimal error rate in a cost-effective manner. In this article, we compared various methods for selecting ancestry informative SNPs using simulations as well as SNP genotype data from samples of admixed populations and showed that the In measure estimates ancestry proportion (in an admixed population) with lower bias and mean square error.
- Published
- 2011
- Full Text
- View/download PDF
307. Database mining for selection of SNP markers useful in admixture mapping
- Author
-
Baye Tesfaye M, Tiwari Hemant K, Allison David B, and Go Rodney C
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 ,Analysis ,QA299.6-433 - Abstract
Abstract Background New technologies make it possible for the first time to genotype hundreds of thousands of SNPs simultaneously. A wealth of genomic information in the form of publicly available databases is underutilized as a potential resource for uncovering functionally relevant markers underlying complex human traits. Given the huge amount of SNP data available from the annotation of human genetic variation, data mining is a reasonable approach to investigating the number of SNPs that are informative for ancestry information. Methods The distribution and density of SNPs across the genome of African and European populations were extensively investigated by using the HapMap, Affymetrix, and Illumina SNP databases. We exploited these resources by mining the data available from each of these databases to prioritize potential candidate SNPs useful for admixture mapping in complex human diseases and traits. Over 4 million SNPs were compared between Africans and Europeans on the basis of a pre-specified recommended allele frequency difference (delta) value of ≥ 0.3. Results The method identified 15% of HapMap, 11% of Affymetrix, and 14% of Illumina SNP sets as candidate SNPs, termed ancestry informative markers (AIMs). These AIM panels with assigned rs numbers, allele frequencies in each ethnic group, delta value, and map positions are all posted on our website http://www.ssg.uab.edu/downloads/admixture_mapping/SNPAIMs.txt. All marker information in this data set is freely and publicly available without restriction. Conclusion The selected SNP sets represent valuable resources for admixture mapping studies. The overlap between selected AIMs by this single measure of marker informativeness in the different platforms is discussed.
- Published
- 2009
- Full Text
- View/download PDF
308. Noninvasive carotid artery testing.
- Author
-
Wong, C Y, MacIntyre, W J, and Go, R T
- Published
- 1995
- Full Text
- View/download PDF
309. Is cumulative frequency of mitochondrial DNA variants a biomarker for colorectal tumor progression?
- Author
-
Okoli Joel, Carey Delicia, Khan Masood, Aikhionbare Felix O, and Go Rodney
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract To examine the relationship between mitochondrial DNA (mtDNA) alterations and colorectal tumorigenesis, we used high-resolution restriction endonucleases and sequencing to assess the mitochondrial genome from three histologic subtypes of colorectal adenomas (tubular = 8; tubulovillous = 9; and villous = 8), colorectal cancer (CRC) tissues = 27, and their matched surrounding normal tissue (MSNT) = 52. The mitochondrial genomes were amplified using 9 pairs of overlapping primers and systematically analyzed by means of high-resolution analysis. DNA fragments showing a shift in banding patterns between the three adenomas, CRC, in comparison to the MSNT were sequenced to identify the mtDNA alterations. A total of thirty-eight germ-line mtDNA variants were observed in this study. Twenty-two of the thirty-eight were identified as mutations and 59% (13 of 22) were silent mutations and one was a 1-bp insertion. Sixteen of thirty-eight were distinct SNPs in flanking regions of the restriction sites and, 6 of the 16 (37%) SNPs were not previously reported. Most of these mutations/SNPs were homoplasmic and distributed in various regions of mitochondrial genes including the 16S and 12S rRNA. Based on our results, mtDNA germline variants increased in prevalence with adenoma CRC progression. To the best of our knowledge, this is the first report to show an increased prevalence of mitochondrial gene variants in CRC tumorigenesis.
- Published
- 2004
- Full Text
- View/download PDF
310. Ancestry reported by white adults with cutaneous melanoma and control subjects in central Alabama
- Author
-
Hollowell William W, Barton Ellen H, Acton Ronald T, Dreibelbis Amy L, Go Rodney CP, and Barton James C
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background We sought to evaluate the hypothesis that the high incidence of cutaneous melanoma in white persons in central Alabama is associated with a predominance of Irish and Scots descent. Methods Frequencies of country of ancestry reports were tabulated. The reports were also converted to scores that reflect proportional countries of ancestry in individuals. Using the scores, we computed aggregate country of ancestry indices as estimates of group ancestry composition. HLA-DRB1*04 allele frequencies and relationships to countries of ancestry were compared in probands and controls. Results were compared to those of European populations with HLA-DRB1*04 frequencies. Results Ninety evaluable adult white cutaneous melanoma probands and 324 adult white controls reported countries of ancestry of their grandparents. The respective frequencies of Ireland, and Scotland and "British Isles" reported countries of ancestry were significantly greater in probands than in controls. The respective frequencies of Wales, France, Italy and Poland were significantly greater in controls. 16.7% of melanoma probands and 23.8% of controls reported "Native American" ancestry; the corresponding "Native American" country of ancestry index was not significantly different in probands and controls. The frequency of HLA-DRB1*04 was significantly greater in probands, but was not significantly associated with individual or aggregate countries of ancestry. The frequency of DRB1*04 observed in Alabama was compared to DRB1*04 frequencies reported from England, Wales, Ireland, Orkney Island, France, Germany, and Australia. Conclusion White adults with cutaneous melanoma in central Alabama have a predominance of Irish, Scots, and "British Isles" ancestry and HLA-DRB1*04 that likely contributes to their high incidence of cutaneous melanoma.
- Published
- 2004
- Full Text
- View/download PDF
311. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2V617F mutation.
- Author
-
Go, R. S.
- Subjects
- *
LETTERS to the editor , *MYELOPROLIFERATIVE neoplasms - Abstract
A letter to the editor is presented in response to an article on myeloproliferative disorders in the previous issue.
- Published
- 2007
- Full Text
- View/download PDF
312. A nurse can safely deliver rituximab over 90 minutes.
- Author
-
Corey P, Go R, and Schaper A
- Published
- 2007
313. Thrombocytopenia after iron dextran administration in a patient with severe iron deficiency anemia.
- Author
-
Go, R S, Porrata, L F, and Call, T G
- Published
- 2000
314. Multiplane Gallium Tomography — A New Test For Assessment for Occupational Lung Disease.
- Author
-
Cordasco, E M, O'Donnell, J, Go, R, Emdur, L, Zenz, C, Mclntyre, W, Gonzalez, I, Eren, M, and Saha, G
- Published
- 1985
315. A positive association between maternal serum zinc concentration andbirth weight
- Author
-
Acton, R. T., Alvarez, J. O., Bonner, J. L., Cutter, G. R., Go, R. C. P., Goldenberg, R. L., Neggers, Y. H., and Roseman, J. M.
- Subjects
BIRTH weight ,PREGNANCY ,ZINC - Published
- 1990
316. Fruit Morphology of Durio zibethinus L. in Jelebu, Negeri Sembilan, Malaysia.
- Author
-
Shamin-Shazwan, K., Razali, N. I. A., Shahari, R., Amri, C. N. A. C., and Go, R.
- Subjects
- *
DURIAN , *FRUIT , *MORPHOLOGY - Abstract
Background: Jelebu is one of Negeri Sembilan districts of Malaysia, famous for its wide variety of D. zibethinus. It is also recognized as the top hotspot area for consumers looking for genuine Durian Kampung. This study aimed at discovering and recording significant morphological data in identification and classification of D. zibethinus fruit in Jelebu. Methods: Fifty-three accessions of durian were observed from January 2020 to September 2020 in accordance with Malaysia's Department of Agriculture guidelines. Result: Forty-one parameters were compiled and divided into two primary morphological data sets: external and internal structures. Size, shape, color and aril characteristics of fruits were several engrossing parameters for identifying and classifying D. zibethinus varieties. Fruit weight varies between 665 g and 2.7 kg, depending on size. The results also revealed six different variants in the fruit shape and color. Aril characteristics included a variety of aril color and thickness ranging from 0.23 cm to 1.17 cm. Therefore, this research revealed that external and internal morphological data from durian fruits were valuable for recognizing and categorizing D. zibethinus Jelebu variants. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
317. Comparison of Persistent Thallium Perfusion Defects by Quantitative Washout Analysis with Thallium Reinjection in Patients with Coronary Artery Disease
- Author
-
Garcia, M. J., Neumann, D., Go, R. T., and Ares, M. A.
- Published
- 1994
- Full Text
- View/download PDF
318. Clonally expanding thymocytes having lineage capability in gamma-ray-induced mouse atrophic thymus.
- Author
-
Yamamoto T, Morita S, Go R, Obata M, Katsuragi Y, Fujita Y, Maeda Y, Yokoyama M, Aoyagi Y, Ichikawa H, Mishima Y, and Kominami R
- Published
- 2010
- Full Text
- View/download PDF
319. 5.6 µm quantum cascade lasers based on a two-material active region composition with a room temperature wall-plug efficiency exceeding 28.
- Author
-
Lyakh, A., Suttinger, M., Go, R., Figueiredo, P., and Todi, A.
- Subjects
- *
QUANTUM cascade lasers , *SEMICONDUCTOR lasers , *CURRENT density (Electromagnetism) , *ELECTRIC currents , *ELECTROMAGNETISM - Abstract
5.6 µm quantum cascade lasers based on the Al0.78In0.22As/In0.69Ga0.31As active region composition with the measured pulsed room temperature wall plug efficiency of 28.3% are reported. Injection efficiency for the upper laser level of 75% was measured for the design by testing devices with variable cavity lengths. A threshold current density of 1.7 kA/cm² and a slope efficiency of 4.9W/A were measured for uncoated 3.15mm x 9 µm lasers. Threshold current density and slope efficiency dependence on temperature in the range from 288K to 348K for the structure can be described by characteristic temperatures T0 ~ 140K and T1 ~ 710 K, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
320. Digitalized herbaria data for assessing extinction risk of the endemic vandaceous orchids of Peninsular Malaysia.
- Author
-
WONG, W. N., YONG, C. S. Y., NAMASIVAYAM, P., GO, R., and ABDULLAH, J. O.
- Subjects
- *
HERBARIA , *ORCHIDS , *BOTANICAL specimens , *ENDANGERED species , *ACQUISITION of data , *BIOLOGICAL extinction - Abstract
Herbaria play important roles in providing information for plant research. However, the data in a herbarium are often hard to obtain unless visits are made to the particular herbarium. Digitalizing the herbaria data becomes a vital move to enable efficient work especially when targeted plant materials could not be easily accessed. There is a lack of efficiency in field data collections due to different constraints limiting the assessment of conservation status of orchids, especially the epiphytic ones. With digital data available from various herbaria abroad and herbarium specimens in local herbaria, a database of orchids in Aeridinae was constructed and used to estimate the Extent of Occurrence of endemic vandaceous orchids in Peninsular Malaysia and their extinction risks were assessed. There are 48 endemic vandaceous orchids in Peninsular Malaysia and most of the species are currently categorized as threatened species. Conservation status and extinction risks of these orchids which were not assessed previously could be used as guidelines in decision making and for effective conservation plans to protect them from risk of extinction as these orchids are highly depending on the forest for survival. [ABSTRACT FROM AUTHOR]
- Published
- 2020
321. Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis.
- Author
-
Muchtar, E., Dean, D. S., Dispenzieri, A., Dingli, D., Buadi, F. K., Lacy, M. Q., Hayman, S. R., Kapoor, P., Leung, N., Russell, S., Lust, J. A., Lin, Yi, Warsame, R., Gonsalves, W., Kourelis, T. V., Go, R. S., Chakraborty, R., Zeldenrust, S., Kyle, R. A., and Rajkumar, S. Vincent
- Subjects
- *
AMIODARONE , *AMYLOIDOSIS , *HYPOTHYROIDISM , *PROTEINURIA , *THYROID diseases , *THYROID hormones , *IMMUNOGLOBULINS , *KIDNEY diseases , *LIVER diseases , *OXIDOREDUCTASES , *SURVIVAL analysis (Biometry) , *THYROTROPIN , *THYROXINE , *COMORBIDITY , *DISEASE prevalence , *THERAPEUTICS - Abstract
Background: Data on the effect of systemic immunoglobulin light chain amyloidosis (AL amyloidosis) on thyroid function are limited.Objective: To assess the prevalence of hypothyroidism in AL amyloidosis patients and determine its predictors.Methods: 1142 newly diagnosed AL amyloidosis patients were grouped based on the thyroid-stimulating hormone (TSH) measurement at diagnosis: hypothyroid group (TSH above upper normal reference; >5 mIU L-1 ; n = 217, 19% of study participants) and euthyroid group (n = 925, 81%). Predictors for hypothyroidism were assessed in a binary multivariate model. Survival between groups was compared using the log-rank test and a multivariate analysis.Results: Patients with hypothyroidism were older, more likely to present with renal and hepatic involvement and had a higher light chain burden compared to patients in the euthyroid group. Higher proteinuria in patients with renal involvement and lower albumin in patients with hepatic involvement were associated with hypothyroidism. In a binary logistic regression model, age ≥65 years, female sex, renal involvement, hepatic involvement, kappa light chain restriction and amiodarone use were independently associated with hypothyroidism. Ninety-three per cent of patients in the hypothyroid group with free thyroxine measurement had normal values, consistent with subclinical hypothyroidism. Patients in the hypothyroid group had a shorter survival compared to patients in the euthyroid group (4-year survival 36% vs 43%; P = 0.008), a difference that was maintained in a multivariate analysis.Conclusion: A significant proportion of patients with AL amyloidosis present with hypothyroidism, predominantly subclinical, which carries a survival disadvantage. Routine assessment of TSH in these patients is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
322. Enhancement of protease production by the optimization of Bacillus subtilis culture medium
- Author
-
Ahmad Adli, A., Go, R., Abd. Aziz, N.A., Cheong, J.Y., and Mustafa, M.
- Subjects
Bacillus subtilis ,Deproteinization ,Shrimp ,Fermentation ,Microbiology ,QR1-502 - Abstract
Aims: Traditionally, crustacean wastes have been managed by using acid and alkali which leads to major environmental issue. However, over the recent years microbial fermentation has gained its way whereby producing similar effects as chemical treatment and a higher quality product can be obtained. Extracellular protease from Bacillus subtilis was used further by optimizing its culture medium to enhance protease production. Methodology and Results: The culture media was optimized with 4 various sources; Shrimp Crab Shell Powder (SCSP), nitrogen sources, inorganic salts, and carbon sources. It was found that culture media supplemented with 9% SCSP, 3% yeast extract, 1% sodium chloride and 9% glucose augmented protease activity up to 565.80 ± 19.41 U/mL compared to the un-optimized media (170.57 ± 6.75 U/mL). By using this optimized media, the ability and efficiency of B. subtilis in a period of 6 days was investigated whereby acid treated shrimp shells (ATSS) and raw shrimp shell powder (RSSP) were used in substitution of SCSP. In a period of 6 days, the protein content in both ATSS and RSSP was found to have been removed up to 60% and 42% respectively. However deproteinization was found to be more efficient in RSSP with the ratio of tyrosine to protein remained constantly high throughout the 6 days period. Conclusion, significance and impact of study: A better, more efficient and environmental friendly method iscontinuously being improvised to manage shrimp wastes with the use of microbes.
- Published
- 2013
323. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
- Author
-
Xin Xin Cao, Benjamin H. Durham, Paul C. Hendrie, Aaron M. Goodman, Jennifer Picarsic, Eric D. Jacobsen, Juvianee Estrada-Veras, Andre Abdo, Michael Girschikofsky, Matthew Collin, Kenneth L. McClain, Mineo Kurokawa, Ronald S. Go, Augusto Vaglio, Mark L. Heaney, Kazuhiro Toyama, Lorenzo Dagna, Julien Haroche, Oshrat Hershkovitz-Rokah, Eli L. Diamond, Ofer Shpilberg, Roei D Mazor, Filip Janku, Fleur Cohen-Aubart, Gaurav Goyal, Goyal, G., Heaney, M. L., Collin, M., Cohen-Aubart, F., Vaglio, A., Durham, B. H., Hershkovitz-Rokah, O., Girschikofsky, M., Jacobsen, E. D., Toyama, K., Goodman, A. M., Hendrie, P., Cao, X. -X., Estrada-Veras, J. I., Shpilberg, O., Abdo, A., Kurokawa, M., Dagna, L., Mcclain, K. L., Mazor, R. D., Picarsic, J., Janku, F., Go, R. S., Haroche, J., and Diamond, E. L.
- Subjects
Male ,Proto-Oncogene Proteins B-raf ,Erdheim-Chester Disease ,medicine.medical_specialty ,genetic structures ,MAP Kinase Signaling System ,medicine.medical_treatment ,Immunology ,MEDLINE ,Disease ,Biochemistry ,Targeted therapy ,Pericarditis ,Fibrosis ,medicine ,Humans ,Molecular Targeted Therapy ,Vemurafenib ,Clinical Trials as Topic ,business.industry ,Cell Biology ,Hematology ,Prognosis ,medicine.disease ,Dermatology ,Histiocytosis, Langerhans-Cell ,Histiocytosis ,Mutation ,Erdheim–Chester disease ,Female ,business ,medicine.drug - Abstract
Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD include central diabetes insipidus, restrictive pericarditis, perinephric fibrosis, and sclerotic bone lesions. The histopathologic diagnosis of ECD is often challenging due to nonspecific inflammatory and fibrotic findings on histopathologic review of tissue specimens. Additionally, the association of ECD with unusual tissue tropism and an insidious onset often results in diagnostic errors and delays. Most patients with ECD require treatment, except for a minority of patients with minimally symptomatic single-organ disease. The first ECD consensus guidelines were published in 2014 on behalf of the physicians and researchers within the Erdheim-Chester Disease Global Alliance. With the recent molecular discoveries and the approval of the first targeted therapy (vemurafenib) for BRAF-V600–mutant ECD, there is a need for updated clinical practice guidelines to optimize the diagnosis and treatment of this disease. This document presents consensus recommendations that resulted from the International Medical Symposia on ECD in 2017 and 2019. Herein, we include the guidelines for the clinical, laboratory, histologic, and radiographic evaluation of ECD patients along with treatment recommendations based on our clinical experience and review of literature in the molecular era.
- Published
- 2020
324. UTILISATION DES ANALYSES CHROMOSOMIQUES EN TANT QUE DOSIMÉTRIE BIOLOGIQUE
- Author
-
BIOLA, M.T. and LE GÔ, R.
- Published
- 1968
- Full Text
- View/download PDF
325. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)
- Author
-
Ivan O. Rosas, Norbert Bräu, Michael Waters, Ronaldo C. Go, Atul Malhotra, Bradley D. Hunter, Sanjay Bhagani, Daniel Skiest, Sinisa Savic, Ivor S. Douglas, Julia Garcia-Diaz, Mariam S. Aziz, Nichola Cooper, Taryn Youngstein, Lorenzo Del Sorbo, David J. De La Zerda, Andrew Ustianowski, Antonio Cubillo Gracian, Kevin G. Blyth, Jordi Carratalà, Bruno François, Thomas Benfield, Derrick Haslem, Paolo Bonfanti, Cor H. van der Leest, Nidhi Rohatgi, Lothar Wiese, Charles Edouard Luyt, Rebecca N. Bauer, Fang Cai, Ivan T. Lee, Balpreet Matharu, Louis Metcalf, Steffen Wildum, Emily Graham, Larry Tsai, Min Bao, Rosas, I, Bräu, N, Waters, M, Go, R, Malhotra, A, Hunter, B, Bhagani, S, Skiest, D, Savic, S, Douglas, I, Garcia-Diaz, J, Aziz, M, Cooper, N, Youngstein, T, Sorbo, L, Zerda, D, Ustianowski, A, Gracian, A, Blyth, K, Carratalà, J, François, B, Benfield, T, Haslem, D, Bonfanti, P, van der Leest, C, Rohatgi, N, Wiese, L, Luyt, C, Bauer, R, Cai, F, Lee, I, Matharu, B, Metcalf, L, Wildum, S, Graham, E, Tsai, L, and Bao, M
- Subjects
Randomised controlled trial ,Coronavirus disease 2019 ,Interleukin-6 ,Prevention ,Clinical Trials and Supportive Activities ,COVID-19 ,Evaluation of treatments and therapeutic interventions ,General Medicine ,Tocilizumab ,Severe acute respiratory syndrome coronavirus-2 ,Vaccine Related ,Infectious Diseases ,Emerging Infectious Diseases ,Good Health and Well Being ,Clinical Research ,6.1 Pharmaceuticals ,Pneumonia & Influenza ,Viral load ,skin and connective tissue diseases ,Infection ,Lung - Abstract
Background: \ud In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay. Longer-term effects of tocilizumab in patients with COVID-19 are unknown. Therefore, the efficacy and safety of tocilizumab in COVID-19 beyond day 28 and its impact on Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) clearance and antibody response in COVACTA were investigated.\ud \ud Methods: \ud Adults in Europe and North America hospitalised with COVID-19 (N = 452) between April 3, 2020 and May 28, 2020 were randomly assigned (2:1) to double-blind intravenous tocilizumab or placebo and assessed for efficacy and safety through day 60. Assessments included mortality, time to hospital discharge, SARS-CoV-2 viral load in nasopharyngeal swab and serum samples, and neutralising anti-SARS-CoV-2 antibodies in serum. ClinicalTrials.gov registration: NCT04320615.\ud \ud Findings: \ud By day 60, 24·5% (72/294) of patients in the tocilizumab arm and 25·0% (36/144) in the placebo arm died (weighted difference –0·5% [95% CI –9·1 to 8·0]), and 67·0% (197/294) in the tocilizumab arm and 63·9% (92/144) in the placebo arm were discharged from the hospital. Serious infections occurred in 24·1% (71/295) of patients in the tocilizumab arm and 29·4% (42/143) in the placebo arm. Median time to negative reverse transcriptase–quantitative polymerase chain reaction result in nasopharyngeal/oropharyngeal samples was 15·0 days (95% CI 14·0 to 21·0) in the tocilizumab arm and 21·0 days (95% CI 14·0 to 28·0) in the placebo arm. All tested patients had positive test results for neutralising anti–SARS-CoV-2 antibodies at day 60.\ud \ud Interpretation: \ud There was no mortality benefit with tocilizumab through day 60. Tocilizumab did not impair viral clearance or host immune response, and no new safety signals were observed. Future investigations may explore potential biomarkers to optimize patient selection for tocilizumab treatment and combination therapy with other treatments.\ud \ud Funding: \ud F. Hoffmann-La Roche Ltd and the US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under OT number HHSO100201800036C.
- Published
- 2021
326. Continuous wave operation of quantum cascade lasers with frequency-shifted feedback.
- Author
-
Lyakh, A., Barron-Jimenez, R., Dunayevskiy, I., Go, R., Tsvid, G., and Patel, C. Kumar N.
- Subjects
- *
QUANTUM cascade lasers , *ELECTRONIC modulators - Abstract
Operation of continuous wave quantum cascade lasers with a frequency-shifted feedback provided by an acousto-optic modulator is reported. Measured linewidth of 1.7 cm-1 for these devices, under CW operating conditions, was in a good agreement with predictions of a model based on frequency-shifted feedback seeded by spontaneous emission. Linewidth broadening was observed for short sweep times, consistent with sound wave grating period variation across the illuminated area on the acousto-optic modulator. Standoff detection capability of the AOM-based QCL setup was demonstrated for several solid materials. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
327. External cavity quantum cascade lasers with ultra rapid acousto-optic tuning.
- Author
-
Lyakh, A., Barron-Jimenez, R., Dunayevskiy, I., Go, R., and Patel, C. Kumar N.
- Subjects
- *
QUANTUM cascade lasers , *ACOUSTO-optical modulation , *PIEZOELECTRIC devices , *MAGNETIC fields , *MAGNETIZATION - Abstract
We report operation of tunable external cavity quantum cascade lasers with emission wavelength controlled by an acousto-optic modulator (AOM). A long-wave infrared quantum cascade laser wavelength tuned from ~8.5 µm to ~9.8 µm when the AOM frequency was changed from ~41MHz to ~49 MHz. The laser delivered over 350 mW of average power at the center of the tuning curve in a linewidth of ~4.7 cm-1. Measured wavelength switching time between any two wavelengths within the tuning range of the QCL was less than 1 µs. Spectral measurements of infrared absorption features of Freon demonstrated a capability of obtaining complete spectral data in less than 20 µs. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
328. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
- Author
-
Frei, E., Visco, C., Xu-Monette, Z. Y., Dirnhofer, S., Dybkær, K., Orazi, A., Bhagat, G., Hsi, E. D., van Krieken, J. H., Ponzoni, M., Go, R. S., Piris, M. A., Møller, M. B., K. H. Young, and Tzankov, A.
- Subjects
- *
PROGNOSIS , *B cell lymphoma , *HEALTH outcome assessment , *CYCLIN E , *CANCER chemotherapy , *IMMUNOHISTOCHEMISTRY , *RITUXIMAB , *ANTINEOPLASTIC agents - Abstract
Background High levels of cyclin E (CCNE) are accompanied by shorter survival in cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP)- treated diffuse large B-cell lymphomas (DLBCL), independent of the international prognostic index (IPI). Data on the prognostic role of CCNE in the 'rituximab (R)-era' are lacking. Methods To test reproducibility and applicability of observations from the 'pre-R era' to the 'R era', we examined the prognostic role of CCNE expression by immunohistochemistry in 1579 DLBCL on tissue microarrays (TMA); 339 patients were treated by CHOP and 635 by R-CHOP. Results 1209 samples (77%) were evaluable; failures were due to missing TMA punches and fixation artefacts. Mean expression of CCNE was 13% (0-85%); applying a cut-off of >16%, 382 DLBCL (31%) were positive. CCNE did not correlate with any of the known variables (IPI, primary site, cell of origin, proliferation, and BCL2- or C-MYC rearrangements). We were able to reproduce data suggesting an IPI- and response to therapy independent, negative prognostic impact of CCNE in CHOP-treated DLBCL patients: CCNE-positive cases had a median survival of 16 months compared with 57 months in negative ones (p=0.012). In R-CHOP-treated patients the prognostic impact of CCNE was abrogated and only IPI, cell of origin and response to therapy had a prognostic significance. Conclusions Addition of R to CHOP overcomes the negative prognostic impact of CCNE in DLBCL. Thus, R not only prolongs survival in DLBCL but also serves a cautionary note that prognostic factors should not be transferred into the 'R era' without proper scientific studies. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
329. Persistent infection with neurotropic herpes viruses and cognitive impairment.
- Author
-
Watson, A. M. M., Prasad, K. M., Klei, L., Wood, J. A., Yolken, R. H., Gur, R. C., Bradford, L. D., Calkins, M. E., Richard, J., Edwards, N., Savage, R. M., Allen, T. B., Kwentus, J., Mcevoy, J. P., Santos, A. B., Wiener, H. W., Go, R. C. P., Perry, R. T., Nasrallah, H. A., and Gur, R. E.
- Subjects
- *
BLOOD testing , *IMMUNOGLOBULIN analysis , *COGNITIVE testing , *COGNITION disorders , *COMPARATIVE studies , *ENCEPHALITIS , *ENZYME-linked immunosorbent assay , *HERPESVIRUS diseases , *HERPESVIRUSES , *RESEARCH funding , *SCHIZOPHRENIA , *PHENOTYPES , *SOCIOECONOMIC factors , *STATISTICAL models , *DESCRIPTIVE statistics , *DISEASE complications - Abstract
Background. Herpes virus infections can cause cognitive impairment during and after acute encephalitis. Although chronic, latent/persistent infection is considered to be relatively benign, some studies have documented cognitive impairment in exposed persons that is untraceable to encephalitis. These studies were conducted among schizophrenia (SZ) patients or older community dwellers, among whom it is difficult to control for the effects of co-morbid illness and medications. To determine whether the associations can be generalized to other groups, we examined a large sample of younger control individuals, SZ patients and their non-psychotic relatives (n = 1852). Method. Using multivariate models, cognitive performance was evaluated in relation to exposures to herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and cytomegalovirus (CMV), controlling for familial and diagnostic status and sociodemographic variables, including occupation and educational status. Composite cognitive measures were derived from nine cognitive domains using principal components of heritability (PCH). Exposure was indexed by antibodies to viral antigens. Results. PCH1, the most heritable component of cognitive performance, declines with exposure to CMV or HSV-1 regardless of case/relative/control group status (p = 1.09 x 10-5 and 0.01 respectively), with stronger association with exposure to multiple herpes viruses (β=-0.25, p = 7.28 x 10-10). There were no significant interactions between exposure and group status. Conclusions. Latent/persistent herpes virus infections can be associated with cognitive impairments regardless of other health status. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
330. A polymorphism in SOD2 is associated with development of Alzheimer’s disease.
- Author
-
Wiener, H. W., Perry, R. T., Chen, Z., Harrell, L. E., and Go, R. C. P.
- Subjects
- *
GENETIC polymorphisms , *SUPEROXIDE dismutase , *GENETICS of Alzheimer's disease , *PHYSIOLOGICAL oxidation , *MEDICAL genetics - Abstract
Genes involved in cellular mechanisms to repair oxidative damage are strong candidates as etiologic factors for Alzheimer’s disease (AD). One important enzyme involved in this mechanism is superoxide dismutase 2 (SOD2). The gene for this enzyme lies within a single haplotype block at 6q25.3, a region showing evidence for linkage to AD in a genome scan. We genotyped four single nucleotide polymorphisms (SNPs) in SOD2 in families of the National Institute of Mental Health-AD Genetics Initiative (ADGI): rs2758346 in the 5′ untranslated region (UTR), rs4880 in exon 2, rs2855116 in intron 3 and rs5746136 in the 3′UTR. Under a dominant model, family-based association tests showed significant evidence for association of AD with the first three loci in a candidate gene set of families with individuals having age of onset of at least 50 years and two affected and one unaffected sibling, and in a late-onset subset of families (families with all affected individuals having age of onset of at least 65 years) from the full ADGI sample. The alleles transmitted more frequently to cases than expected under the null hypothesis were T, C, G, and G. Global tests of the transmission of haplotypes indicate that the first two loci have the most consistent association with risk of AD. Because of the high linkage disequilibrium in this small (14 kb) gene, and the presence of 100 SNPs in this gene, 26 of which may have functional significance, additional genotyping and sequencing are needed to identify the functionally relevant SNP. We discuss the importance of our findings and the relevance of SOD2 to AD risk. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
331. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status:A report from an international DLBCL rituximab-CHOP consortium program study
- Author
-
Jane N. Winter, Huan You Wang, Stacey S O'Neill, Santiago Montes-Moreno, J. Han van Krieken, Govind Bhagat, Wei-Min Liu, April Chiu, Yong Li, Stephan Dirnhofer, Cherie H. Dunphy, Karen Dybkær, Brad S. Kahl, Zijun Y. Xu-Monette, Emanuele S.G. d'Amore, Yan Li, Ken H. Young, Eric D. His, Miguel A. Piris, Carlo Visco, L. Jeffrey Medeiros, Xiaoying Zhao, Qin Huang, Ronald S. Go, Maurilio Ponzoni, Attilio Orazi, Michael Boe Møller, Roberto N. Miranda, Alexander Tzankov, Weiyun Z. Ai, Andrés J.M. Ferreri, Lin Wu, Yu Chuan Tai, Youli Zu, William W.L. Choi, X. Frank Zhao, Visco, C, Tzankov, A, Xu Monette, Zy, Miranda, Rn, Tai, Yc, Li, Y, Liu, Wm, D'Amore, E, Montes Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Wang, Hy, Dunphy, Ch, O' Neill, S, Hsi, Ed, Zhao, Xf, Choi, Ww, Zhao, X, van Krieken, Jh, Huang, Q, Ai, W, Ponzoni, Maurilio, Ferreri, Aj, Kahl, B, Winter, Jn, Go, R, Dirnhofer, S, Piris, Ma, Møller, Mb, Wu, L, Medeiros, Lj, and Young, K. H.
- Subjects
Male ,Lymphoma ,Genes, myc ,CHOP ,Translocation, Genetic ,Antibodies, Monoclonal, Murine-Derived ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Monoclonal ,Antineoplastic Combined Chemotherapy Protocols ,80 and over ,Aged, 80 and over ,0303 health sciences ,medicine.diagnostic_test ,Articles ,Hematology ,myc ,Middle Aged ,Prognosis ,Translational research Tissue engineering and pathology [ONCOL 3] ,Diffuse ,3. Good health ,Adolescent ,Adult ,Aged ,Chromosomes, Human, Pair 14 ,Chromosomes, Human, Pair 18 ,Cyclophosphamide ,Doxorubicin ,Female ,Gene Expression Profiling ,Germinal Center ,Humans ,Lymphoma, Large B-Cell, Diffuse ,Prednisone ,Proto-Oncogene Proteins c-bcl-2 ,Vincristine ,Young Adult ,030220 oncology & carcinogenesis ,Rituximab ,medicine.drug ,Human ,Murine-Derived ,Translocation ,Biology ,Antibodies ,Chromosomes ,03 medical and health sciences ,Genetic ,medicine ,Large B-Cell ,030304 developmental biology ,Pair 18 ,Pair 14 ,Germinal center ,medicine.disease ,Gene expression profiling ,Genes ,Cancer research ,Diffuse large B-cell lymphoma ,Fluorescence in situ hybridization - Abstract
Contains fulltext : 118936.pdf (Publisher’s version ) (Open Access) Diffuse large B-cell lymphoma can be classified by gene expression profiling into germinal center and activated B-cell subtypes with different prognoses after rituximab-CHOP. The importance of previously recognized prognostic markers, such as Bcl-2 protein expression and BCL2 gene abnormalities, has been questioned in the new therapeutic era. We analyzed Bcl-2 protein expression, and BCL2 and MYC gene abnormalities by interphase fluorescence in situ hybridization in 327 patients with de novo disease treated with rituximab-CHOP. Isolated BCL2 and MYC rearrangements were not predictive of outcome in our patients as a whole, but only in those with the germinal center subtype of lymphoma. The prognostic relevance of isolated MYC rearrangements was weaker than that of BCL2 isolated translocations, but was probably limited by the rarity of the rearrangements. Seven of eight patients with double hit lymphoma had the germinal center subtype with poor outcome. The germinal center subtype patients with isolated BCL2 translocations had significantly worse outcome than the patients without BCL2 rearrangements (P=0.0002), and their outcome was similar to that of patients with the activated B-cell subtype (P=0.30), but not as bad as the outcome of patients with double hit lymphoma (P
- Published
- 2013
332. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
- Author
-
Yong Li, Zijun Y. Xu-Monette, Karen Dybkær, Mingzhi Zhang, Jooryung Huh, Michael Boe Møller, J. Han van Krieken, Li Zhang, Lin Wu, Roberto N. Miranda, Alexander Tzankov, Qin Huang, Youli Zu, L. Jeffrey Medeiros, Shimin Hu, Miguel A. Piris, Maurilio Ponzoni, Carlo Visco, Andrés J.M. Ferreri, Ronald S. Go, Govind Bhagat, April Chiu, Kristy L. Richards, Ling Li, Aarthi Balasubramanyam, Xiaoying Zhao, William W.L. Choi, Santiago Montes-Moreno, Jane N. Winter, Ken H. Young, Wei-Min Liu, Ganiraju C. Manyam, Eric D. Hsi, Weiyun Z. Ai, Attilio Orazi, Hu, S, Xu Monette, Zy, Balasubramanyam, A, Manyam, Gc, Visco, C, Tzankov, A, Liu, Wm, Miranda, Rn, Zhang, L, Montes Moreno, S, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, Kl, Hsi, Ed, Choi, Ww, Han van Krieken, J, Huang, Q, Huh, J, Ai, W, Ponzoni, Maurilio, Ferreri, Aj, Zhao, X, Winter, Jn, Zhang, M, Li, L, Møller, Mb, Piris, Ma, Li, Y, Go, R, Wu, L, Medeiros, Lj, and Young, K. H.
- Subjects
Male ,CD30 ,Immunology ,Ki-1 Antigen ,Antineoplastic Agents ,CHOP ,Biology ,Biochemistry ,Antigens, CD30 ,Disease-Free Survival ,Antibodies, Monoclonal, Murine-Derived ,immune system diseases ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Brentuximab vedotin ,Cyclophosphamide ,integumentary system ,Germinal center ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Prognosis ,Survival Analysis ,Lymphoma ,Gene expression profiling ,Gene Expression Regulation, Neoplastic ,Treatment Outcome ,Doxorubicin ,Vincristine ,Multivariate Analysis ,Cancer research ,Prednisone ,Rituximab ,Female ,Lymphoma, Large B-Cell, Diffuse ,Transcriptome ,Diffuse large B-cell lymphoma ,medicine.drug ,Follow-Up Studies - Abstract
CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de novo DLBCL patients. CD30 was expressed in ∼14% of DLBCL patients. Patients with CD30(+) DLBCL had superior 5-year overall survival (CD30(+), 79% vs CD30(-), 59%; P = .001) and progression-free survival (P = .003). The favorable outcome of CD30 expression was maintained in both the germinal center B-cell and activated B-cell subtypes. Gene expression profiling revealed the upregulation of genes encoding negative regulators of nuclear factor κB activation and lymphocyte survival, and downregulation of genes encoding B-cell receptor signaling and proliferation, as well as prominent cytokine and stromal signatures in CD30(+) DLBCL patients, suggesting a distinct molecular basis for its favorable outcome. Given the superior prognostic value, unique gene expression signature, and significant value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trials, it seems appropriate to consider CD30(+) DLBCL as a distinct subgroup of DLBCL.
- Published
- 2013
333. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy:a report from the international DLBCL rituximab-CHOP consortium program
- Author
-
L. Jeffrey Medeiros, William W.L. Choi, Eric D. Hsi, Weiyun Z. Ai, Sa A. Wang, Youli Zu, Yong Li, Govind Bhagat, Carlos E. Bueso-Ramos, Andrés J.M. Ferreri, Alexander Tzankov, Qin Huang, Ronald S. Go, Michael Boe Møller, Kristy L. Richards, Zijun Y. Xu-Monette, Miguel A. Piris, Santiago Montes-Moreno, Carlo Visco, April Chiu, Xiaoying Zhao, J. Han van Krieken, Jooryung Huh, Louise Kristensen, Wenwei Hu, Maurilio Ponzoni, Ken H. Young, Lin Wu, Karen Dybkær, Jane N. Winter, Lei Fan, Wayne Tam, Ganiraju C. Manyam, Xu Monette, Zy, Møller, Mb, Tzankov, A, Montes Moreno, S, Hu, W, Manyam, Gc, Kristensen, L, Fan, L, Visco, C, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Bhagat, G, Richards, Kl, Hsi, Ed, Choi, Ww, van Krieken, Jh, Huang, Q, Huh, J, Ai, W, Ponzoni, Maurilio, Ferreri, Aj, Wu, L, Zhao, X, Bueso Ramos, Ce, Wang, Sa, Go, R, Li, Y, Winter, Jn, Piris, Ma, Medeiros, Lj, and Young, Kh
- Subjects
Male ,CHOP ,Biochemistry ,Antibodies, Monoclonal, Murine-Derived ,immune system diseases ,Risk Factors ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,P53-MDM2 FEEDBACK LOOP ,MUTANT P53 ,IN-VIVO ,Lymphoid Neoplasia ,medicine.diagnostic_test ,ONCOPROTEIN MDM2 ,Proto-Oncogene Proteins c-mdm2 ,Hematology ,Middle Aged ,Translational research Tissue engineering and pathology [ONCOL 3] ,Phenotype ,Treatment Outcome ,Vincristine ,SURVIVAL ,Rituximab ,Female ,Lymphoma, Large B-Cell, Diffuse ,medicine.drug ,SINGLE NUCLEOTIDE POLYMORPHISM ,EXPRESSION ,Adult ,Genotype ,Immunology ,Single-nucleotide polymorphism ,Biology ,medicine ,OSCILLATIONS ,Humans ,Immunologic Factors ,NON-HODGKINS-LYMPHOMA ,neoplasms ,Cyclophosphamide ,Aged ,Gene Expression Profiling ,OVEREXPRESSION ,Cell Biology ,medicine.disease ,Lymphoma ,Gene expression profiling ,enzymes and coenzymes (carbohydrates) ,Doxorubicin ,Cancer research ,Prednisone ,Tumor Suppressor Protein p53 ,Diffuse large B-cell lymphoma ,Fluorescence in situ hybridization ,Follow-Up Studies - Abstract
MDM2 is a key negative regulator of the tumor suppressor p53, however, the prognostic significance of MDM2 overexpression in diffuse large B-cell lymphoma (DLBCL) has not been defined convincingly. In a p53-genetically defined large cohort of de novo DLBCL patients treated with R-CHOP chemotherapy, we assessed MDM2 and p53 expression by immunohistochemistry (n=478), MDM2 gene amplification by fluorescence in situ hybridization (n=364), and a single nucleotide polymorphism in the MDM2 promoter, SNP309, by SNP genotyping assay (n=108). Our results show that MDM2 overexpression, unlike p53 overexpression, is not a significant prognostic factor in overall DLBCL. Both MDM2 and p53 overexpression does not predict for an adverse clinical outcome in patients with wild-type p53, but predicts for significantly poorer survival in patients with mutated p53. Variable p53 activities may ultimately determine the survival differences as suggested by the gene expression profiling analysis. MDM2 amplification was observed in 3 of 364 (0.8%) patients with high MDM2 expression. Presence of SNP309 did not correlate with MDM2 expression and survival. This study indicates that evaluation of MDM2 and p53 expression correlating with TP53 genetic status is essential to assess their prognostic significance, and important for designing therapeutic strategies that target the MDM2-p53 interaction. MDM2 is a key negative regulator of the tumor suppressor p53, however, the prognostic significance of MDM2 overexpression in diffuse large B-cell lymphoma (DLBCL) has not been defined convincingly. In a p53-genetically defined large cohort of de novo DLBCL patients treated with R-CHOP chemotherapy, we assessed MDM2 and p53 expression by immunohistochemistry (n=478), MDM2 gene amplification by fluorescence in situ hybridization (n=364), and a single nucleotide polymorphism in the MDM2 promoter, SNP309, by SNP genotyping assay (n=108). Our results show that MDM2 overexpression, unlike p53 overexpression, is not a significant prognostic factor in overall DLBCL. Both MDM2 and p53 overexpression does not predict for an adverse clinical outcome in patients with wild-type p53, but predicts for significantly poorer survival in patients with mutated p53. Variable p53 activities may ultimately determine the survival differences as suggested by the gene expression profiling analysis. MDM2 amplification was observed in 3 of 364 (0.8%) patients with high MDM2 expression. Presence of SNP309 did not correlate with MDM2 expression and survival. This study indicates that evaluation of MDM2 and p53 expression correlating with TP53 genetic status is essential to assess their prognostic significance, and important for designing therapeutic strategies that target the MDM2-p53 interaction.
- Published
- 2013
334. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures:a report from The International DLBCL Rituximab-CHOP Consortium Program
- Author
-
Karen Dybkær, William W.L. Choi, Yong Li, J. Han van Krieken, Meifeng Tu, Zijun Y. Xu-Monette, L. Jeffrey Medeiros, Weina Chen, April Chiu, Andrés J.M. Ferreri, Aarthi Balasubramanyam, Miguel A. Piris, Randy D. Gascoyne, Jooryung Huh, Fan Zhou, Govind Bhagat, Eric D. Hsi, Weiyun Z. Ai, Carlo Visco, Lin Wu, Qin Huang, Graham W. Slack, Maurilio Ponzoni, Ronald S. Go, Kristy L. Richards, Michael Boe Møller, Attilio Orazi, Youli Zu, Ken H. Young, Xiaoying Zhao, Santiago Montes-Moreno, Roberto N. Miranda, Daina Variakojis, Alexander Tzankov, Shimin Hu, Tina Green, Wei-Min Liu, Hu, S, Xu Monette, Zy, Tzankov, A, Green, T, Wu, L, Balasubramanyam, A, Liu, Wm, Visco, C, Li, Y, Miranda, Rn, Montes Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, Kl, Hsi, Ed, Choi, Ww, Zhao, X, van Krieken, Jh, Huang, Q, Huh, J, Ai, W, Ponzoni, Maurilio, Ferreri, Aj, Zhou, F, Slack, Gw, Gascoyne, Rd, Tu, M, Variakojis, D, Chen, W, Go, R, Piris, Ma, Møller, Mb, Medeiros, Lj, and Young, Kh
- Subjects
Male ,Lymphoma ,International Cooperation ,Plenary Paper ,CHOP ,Lymphocyte Activation ,Biochemistry ,Cohort Studies ,Antibodies, Monoclonal, Murine-Derived ,immune system diseases ,Risk Factors ,hemic and lymphatic diseases ,Monoclonal ,Antineoplastic Combined Chemotherapy Protocols ,80 and over ,Regulation of gene expression ,Aged, 80 and over ,Hematology ,Adult ,Aged ,B-Lymphocyte Subsets ,Cyclophosphamide ,Doxorubicin ,Female ,Gene Expression Regulation, Neoplastic ,Humans ,Lymphoma, Large B-Cell, Diffuse ,Middle Aged ,Prednisone ,Prognosis ,Proto-Oncogene Proteins c-bcl-2 ,Proto-Oncogene Proteins c-myc ,Retrospective Studies ,Rituximab ,Survival Analysis ,Vincristine ,Transcriptome ,Translational research Tissue engineering and pathology [ONCOL 3] ,Diffuse ,medicine.anatomical_structure ,biological phenomena, cell phenomena, and immunity ,medicine.drug ,Murine-Derived ,Immunology ,Biology ,Antibodies ,Large B-Cell ,medicine ,neoplasms ,B cell ,Neoplastic ,Germinal center ,Cell Biology ,medicine.disease ,Gene Expression Regulation ,Cancer research ,Diffuse large B-cell lymphoma - Abstract
Contains fulltext : 118768.pdf (Publisher’s version ) (Closed access) Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)-like and unfavorable activated B-cell (ABC)-like subtypes based on gene expression signatures. In this study, we analyzed 893 de novo DLBCL patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). We show that MYC/BCL2 protein coexpression occurred significantly more commonly in the ABC subtype. Patients with the ABC or GCB subtype of DLBCL had similar prognoses with MYC/BCL2 coexpression and without MYC/BCL2 coexpression. Consistent with the notion that the prognostic difference between the 2 subtypes is attributable to MYC/BCL2 coexpression, there is no difference in gene expression signatures between the 2 subtypes in the absence of MYC/BCL2 coexpression. DLBCL with MYC/BCL2 coexpression demonstrated a signature of marked downregulation of genes encoding extracellular matrix proteins, those involving matrix deposition/remodeling and cell adhesion, and upregulation of proliferation-associated genes. We conclude that MYC/BCL2 coexpression in DLBCL is associated with an aggressive clinical course, is more common in the ABC subtype, and contributes to the overall inferior prognosis of patients with ABC-DLBCL. In conclusion, the data suggest that MYC/BCL2 coexpression, rather than cell-of-origin classification, is a better predictor of prognosis in patients with DLBCL treated with R-CHOP.
- Published
- 2013
335. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma
- Author
-
C. Visco, Stefan Dirnhofer, Alexandar Tzankov, Michael Boe Møller, Karen Dybkær, Ronald S. Go, Attilio Orazi, M. Ponzoni, Govind Bhagat, E Frei, J.H.J.M. van Krieken, M A Piris, Eric D. Hsi, Ken H. Young, Zijun Y. Xu-Monette, Frei, E, Visco, C, Xu Monette, Zy, Dirnhofer, S, Dybkær, K, Orazi, A, Bhagat, G, Hsi, Ed, van Krieken, Jh, Ponzoni, Maurilio, Go, R, Piris, Ma, Møller, Mb, Young, Kh, and Tzankov, A.
- Subjects
Oncology ,Male ,Pathology ,Cyclin E ,Lymphoma ,CHOP ,Cohort Studies ,Antibodies, Monoclonal, Murine-Derived ,International Prognostic Index ,immune system diseases ,hemic and lymphatic diseases ,Monoclonal ,Antineoplastic Combined Chemotherapy Protocols ,Oncogene Proteins ,Cell Cycle Regulation ,Haematopathology ,Tissue microarray ,General Medicine ,Middle Aged ,Prognosis ,Translational research Tissue engineering and pathology [ONCOL 3] ,Diffuse ,Immunohistochemistry ,Treatment Outcome ,Aged ,Antineoplastic Agents ,Cyclophosphamide ,Doxorubicin ,Female ,Follow-Up Studies ,Humans ,Lymphoma, Large B-Cell, Diffuse ,Prednisone ,Reproducibility of Results ,Rituximab ,Tissue Array Analysis ,Vincristine ,medicine.drug ,Murine-Derived ,medicine.medical_specialty ,Antibodies ,Pathology and Forensic Medicine ,Internal medicine ,Large B-Cell ,medicine ,business.industry ,medicine.disease ,business ,Diffuse large B-cell lymphoma - Abstract
BackgroundHigh levels of cyclin E (CCNE) are accompanied by shorter survival in cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP)-treated diffuse large B-cell lymphomas (DLBCL), independent of the international prognostic index (IPI). Data on the prognostic role of CCNE in the ‘rituximab (R)-era’ are lacking.MethodsTo test reproducibility and applicability of observations from the ‘pre-R era’ to the ‘R era’, we examined the prognostic role of CCNE expression by immunohistochemistry in 1579 DLBCL on tissue microarrays (TMA); 339 patients were treated by CHOP and 635 by R-CHOP.Results1209 samples (77%) were evaluable; failures were due to missing TMA punches and fixation artefacts. Mean expression of CCNE was 13% (0–85%); applying a cut-off of >16%, 382 DLBCL (31%) were positive. CCNE did not correlate with any of the known variables (IPI, primary site, cell of origin, proliferation, and BCL2- or C-MYC rearrangements). We were able to reproduce data suggesting an IPI- and response to therapy independent, negative prognostic impact of CCNE in CHOP-treated DLBCL patients: CCNE-positive cases had a median survival of 16 months compared with 57 months in negative ones (p=0.012). In R-CHOP-treated patients the prognostic impact of CCNE was abrogated and only IPI, cell of origin and response to therapy had a prognostic significance.ConclusionsAddition of R to CHOP overcomes the negative prognostic impact of CCNE in DLBCL. Thus, R not only prolongs survival in DLBCL but also serves a cautionary note that prognostic factors should not be transferred into the ‘R era’ without proper scientific studies.
- Published
- 2013
336. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program
- Author
-
Lin Wu, Maurilio Ponzoni, Karen Dybkær, Youli Zu, J. Han van Krieken, Qin Huang, Eric D. Hsi, Weiyun Z. Ai, Govind Bhagat, Ronald S. Go, Dehui Zou, William W.L. Choi, Kristy L. Richards, Michael W. Gordon, Miguel A. Piris, L. Jeffrey Medeiros, Carlo Visco, Michael Boe Møller, Lugui Qiu, Attilio Orazi, Zijun Y. Xu-Monette, Yong Li, Kenneth S. Ramos, Alexander Tzankov, Ken H. Young, Santiago Montes-Moreno, Andrés J.M. Ferreri, Jane N. Winter, Michael Wang, Li, Y, Gordon, Mw, Xu Monette, Zy, Visco, C, Tzankov, A, Zou, D, Qiu, L, Montes Moreno, S, Dybkaer, K, Orazi, A, Zu, Y, Bhagat, G, Richards, Kl, Hsi, Ed, Choi, Ww, van Krieken, Jh, Huang, Q, Ai, W, Ponzoni, Maurilio, Ferreri, Aj, Winter, Jn, Go, R, Piris, Ma, Møller, Mb, Wu, L, Wang, M, Ramos, K, Medeiros, Lj, and Young, K. H.
- Subjects
Untranslated region ,Lymphoma ,endocrine system diseases ,Kaplan-Meier Estimate ,CHOP ,Biochemistry ,Antibodies, Monoclonal, Murine-Derived ,immune system diseases ,hemic and lymphatic diseases ,Monoclonal ,Antineoplastic Combined Chemotherapy Protocols ,Coding region ,3' Untranslated Regions ,Tumor ,Lymphoid Neoplasia ,Single Nucleotide ,Hematology ,Prognosis ,Translational research Tissue engineering and pathology [ONCOL 3] ,Diffuse ,Vincristine ,Rituximab ,Lymphoma, Large B-Cell, Diffuse ,medicine.drug ,Murine-Derived ,5' Untranslated Regions ,Antineoplastic Agents ,Cell Line, Tumor ,Cyclophosphamide ,Doxorubicin ,Genetic Testing ,Germ-Line Mutation ,Humans ,MicroRNAs ,Polymorphism, Single Nucleotide ,Prednisone ,Retrospective Studies ,Tumor Suppressor Protein p53 ,Immunology ,Biology ,Antibodies ,Cell Line ,Germline mutation ,stomatognathic system ,Large B-Cell ,medicine ,Polymorphism ,neoplasms ,Three prime untranslated region ,Cell Biology ,medicine.disease ,Molecular biology ,Diffuse large B-cell lymphoma - Abstract
Contains fulltext : 185425.pdf (Publisher’s version ) (Closed access) We identified multiple single nucleotide variants (SNVs) in the TP53 3' untranslated region (3'UTR) in tumor specimens from 244 patients with diffuse large B-cell lymphoma (DLBCL). Patients carrying a wild-type TP53 coding sequence (CDS) and 1 or more 3'UTR SNVs had a better 5-year survival rate than patients carrying a wild-type CDS and the reference 3'UTR, yet there is no statistically significance difference in overall survival (OS). In contrast, 3'UTR variation predicted poorer OS for patients with a mutant TP53 CDS. We then sequenced TP53 3'UTR in 247 additional DLBCL patients as a validation set. Altogether, we identified 187 novel SNVs; 36 occurred at least twice. Most of the newly identified 3'UTR SNVs were located at sites that are complementary to seed sequences of microRNAs (miRNAs) that are predicted or experimentally known to target TP53. Three SNVs disrupt the seed match between miR-125b and the TP53 3'UTR, thereby impeding suppression of p53 by this miRNA. In addition, a germline SNV (rs78378222) located in the TP53 polyadenylation signal resulted in downregulation of both p53 messenger RNA and protein levels and reduction of cellular apoptosis. This study is the first to demonstrate the prognostic value of the TP53 3'UTR in cancer.
- Published
- 2013
337. Utilization of chromosome analysis as an irradiation dosemeter; 8. Congres national sur le controle des rayonnements ionisants
- Author
-
Le Go, R
- Published
- 1976
338. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP:report from an International DLBCL Rituximab-CHOP Consortium Program Study
- Author
-
Jane N. Winter, Lin Wu, Qin Huang, Youli Zu, Zijun Y. Xu-Monette, Wei Xu, Ronald S. Go, Jooryung Huh, Fan Zhou, April Chiu, Maurilio Ponzoni, Brad S. Kahl, Attilio Orazi, Govind Bhagat, Kristy L. Richards, Jianyong Li, Andrés J.M. Ferreri, Santiago Montes-Moreno, Roberto N. Miranda, Eric D. Hsi, Michael Boe Møller, Alexander Tzankov, Lynne V. Abruzzo, Xiaoying Zhao, Weiyun Z. Ai, Yu Chuan Tai, X. Frank Zhao, Miguel A. Piris, William W.L. Choi, Carlo Visco, Yong Li, Karen Dybkær, Ken H. Young, L. Jeffrey Medeiros, J. Han van Krieken, Wei-Min Liu, Xu Monette, Zy, Wu, L, Visco, C, Tai, Yc, Tzankov, A, Liu, Wm, Montes Moreno, S, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, Kl, Hsi, Ed, Zhao, Xf, Choi, Ww, Zhao, X, van Krieken, Jh, Huang, Q, Huh, J, Ai, W, Ponzoni, Maurilio, Ferreri, Aj, Zhou, F, Kahl, B, Winter, Jn, Xu, W, Li, J, Go, R, Li, Y, Piris, Ma, Møller, Mb, Miranda, Rn, Abruzzo, Lv, Medeiros, Lj, and Young, K. H.
- Subjects
Male ,Cancer Research ,Lymphoma ,Loss of Heterozygosity ,Gene mutation ,CHOP ,Biochemistry ,Cohort Studies ,Antibodies, Monoclonal, Murine-Derived ,Mutation Rate ,Prednisone ,immune system diseases ,hemic and lymphatic diseases ,Monoclonal ,Antineoplastic Combined Chemotherapy Protocols ,Hematology ,Exons ,Middle Aged ,Prognosis ,Diffuse ,Translational research Tissue engineering and pathology [ONCOL 3] ,Gene Expression Regulation, Neoplastic ,Treatment Outcome ,Oncology ,Vincristine ,Rituximab ,Female ,Lymphoma, Large B-Cell, Diffuse ,medicine.drug ,Murine-Derived ,Adult ,Aged ,Alleles ,Computational Biology ,Cyclophosphamide ,Doxorubicin ,Gene Deletion ,Gene Expression Profiling ,Humans ,Mutation, Missense ,Neoplasm Staging ,Tumor Suppressor Protein p53 ,Mutation ,Immunology ,Biology ,Antibodies ,Large B-Cell ,medicine ,neoplasms ,Neoplastic ,Germinal center ,Cell Biology ,medicine.disease ,Gene Expression Regulation ,Cancer research ,Missense ,Diffuse large B-cell lymphoma - Abstract
Contains fulltext : 108767.pdf (Publisher’s version ) (Closed access) TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. However, its prognostic value in the rituximab immunochemotherapy era remains undefined. In the present study of a large cohort of DLBCL patients treated with rituximab plus CHOP (R-CHOP), we show that those with TP53 mutations had worse overall and progression-free survival compared with those without. Unlike earlier studies of patients treated with CHOP, TP53 mutation has predictive value for R-CHOP-treated patients with either the germinal center B-cell or activated B-cell DLBCL subtypes. Furthermore, we identified the loop-sheet-helix and L3 motifs in the DNA-binding domain to be the most critical structures for maintaining p53 function. In contrast, TP53 deletion and loss of heterozygosity did not confer worse survival. If gene mutation data are not available, immunohistochemical analysis showing > 50% cells expressing p53 protein is a useful surrogate and was able to stratify patients with significantly different prognoses. We conclude that assessment of TP53 mutation status is important for stratifying R-CHOP-treated patients into distinct prognostic subsets and has significant value in the design of future therapeutic strategies.
- Published
- 2012
339. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
- Author
-
C Visco, Y Li, Z Y Xu-Monette, R N Miranda, T M Green, A Tzankov, W Wen, W-m Liu, B S Kahl, E S G d'Amore, S Montes-Moreno, K Dybkær, A Chiu, W Tam, A Orazi, Y Zu, G Bhagat, J N Winter, H-Y Wang, S O'Neill, C H Dunphy, E D Hsi, X F Zhao, R S Go, W W L Choi, F Zhou, M Czader, J Tong, X Zhao, J H van Krieken, Q Huang, W Ai, J Etzell, M Ponzoni, A J M Ferreri, M A Piris, M B Møller, C E Bueso-Ramos, L J Medeiros, L Wu, K H Young, Visco, C, Li, Y, Xu Monette, Zy, Miranda, Rn, Green, Tm, Tzankov, A, Wen, W, Liu, Wm, Kahl, B, D'Amore, Esg, Montes Moreno, S, Dybkaer, K, Chiu, A, Tam, W, Orazi, A, Zu, Y, Bhagat, G, Winter, Jn, Wang, Hy, O'Neill, S, Dunphy, Ch, Hsi, Ed, Zhao, Xf, Go, R, Choi, Wwl, Zhou, F, Czader, M, Tong, J, Zhao, X, van Krieken, Jh, Huang, Q, Ai, W, Etzell, J, Ponzoni, Maurilio, Ferreri, Ajm, Piris, Ma, Moller, Mb, Bueso Ramos, Ce, Medeiros, Lj, Wu, L, and Young, Kh
- Subjects
Male ,Cancer Research ,Lymphoma ,CHOP ,Immunoenzyme Techniques ,Antibodies, Monoclonal, Murine-Derived ,International Prognostic Index ,immune system diseases ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,Cyclophosphamide ,Doxorubicin ,Female ,Humans ,Immunophenotyping ,Lymphoma, Large B-Cell, Diffuse ,Middle Aged ,Oligonucleotide Array Sequence Analysis ,Prednisone ,Prognosis ,Rituximab ,Survival Rate ,Tissue Array Analysis ,Vincristine ,Algorithms ,Gene Expression Profiling ,Monoclonal ,Tissue microarray ,Tumor ,Hematology ,BCL6 ,Translational research Tissue engineering and pathology [ONCOL 3] ,Diffuse ,Oncology ,Tumor Markers, Biological ,Algorithm ,medicine.drug ,Murine-Derived ,Biology ,Article ,Antibodies ,medicine ,Large B-Cell ,Germinal center ,medicine.disease ,Gene expression profiling ,Diffuse large B-cell lymphoma ,Biomarkers - Abstract
Gene expression profiling (GEP) has stratified diffuse large B-cell lymphoma (DLBCL) into molecular subgroups that correspond to different stages of lymphocyte development-namely germinal center B-cell-like and activated B-cell-like. This classification has prognostic significance, but GEP is expensive and not readily applicable into daily practice, which has lead to immunohistochemical algorithms proposed as a surrogate for GEP analysis. We assembled tissue microarrays from 475 de novo DLBCL patients who were treated with rituximab-CHOP chemotherapy. All cases were successfully profiled by GEP on formalin-fixed, paraffin-embedded tissue samples. Sections were stained with antibodies reactive with CD10, GCET1, FOXP1, MUM1, and BCL6 and cases were classified following a rationale of sequential steps of differentiation of B-cells. Cutoffs for each marker were obtained using receiver operating characteristic curves, obviating the need for any arbitrary method. An algorithm based on the expression of CD10, FOXP1, and BCL6 was developed that had a simpler structure than other recently proposed algorithms and 92.6% concordance with GEP. In multivariate analysis, both the International Prognostic Index and our proposed algorithm were significant independent predictors of progression-free and overall survival. In conclusion, this algorithm effectively predicts prognosis of DLBCL patients matching GEP subgroups in the era of rituximab therapy.Leukemia accepted article preview online, 22 March 2012; doi:10.1038/leu.2012.83.
- Published
- 2012
340. Utilization of chromosome analysis as an irradiation dosimeter
- Author
-
Le Go, R
- Published
- 1974
341. UTILIZATION OF CHROMOSOME ANALYSES IN BIOLOGICAL DOSIMETRY.
- Author
-
Le Go, R
- Published
- 1969
342. A DOCUMENT ON THE NOTION OF ''DOSE'' WITH THE IRRADIATED MAN.
- Author
-
Le Go, R
- Published
- 1968
343. THREE ASPECTS OF THE DOSE CONCEPT FOR IRRADIATED PERSONS.
- Author
-
Le Go, R
- Published
- 1968
344. AN APPROACH TO AUTOMATED CHROMOSOME ANALYSIS.
- Author
-
Le Go, R
- Published
- 1972
345. Chromosomial dosemeter, its interest for the estimation of irradiation doses received by man.
- Author
-
le Go, R
- Published
- 1972
346. QUANTITATIVE ASPECTS OF HEMATOLOGICAL EFFECTS OF IONIZING RADIATION.
- Author
-
Le Go, R
- Published
- 1966
347. COMPARATIVE STUDY OF $sup 137$Cs $gamma$ RADIATION AND ULTRAVIOLET RADIATIONS. MEASUREMENT OF THE DOSE ABSORBED BY HUMAN BLOOD TISSUE AS A FUNCTION OF HEMATOCRIT.
- Author
-
Le Go, R
- Published
- 1970
348. PRACTICAL ATTITUDE OF THE PHYSICIAN IN CASE OF ACCIDENTAL OVEREXPOSURE.
- Author
-
Le Go, R
- Published
- 1971
349. HAEMATOLOGICAL DOSIMETER.
- Author
-
Le Go, R
- Published
- 1971
350. CHROMOSOME AS A DOSIMETER.
- Author
-
Le Go, R
- Published
- 1971
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.